Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-07-07

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines, led by CASGEVY and a broader pipeline in in vivo editing, cell therapy, regenerative medicine, and partnered RNA therapeutics.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First Product Proven, Platform Proof Pending

The company has crossed the hardest first hurdle by launching the first approved CRISPR therapy, but the stock still needs broader owned-program proof to fully rerate. The opportunity is meaningful if commercial traction and one additional franchise convert scientific credibility into durable economics.

Analysis

Thesis

CRISPR Therapeutics already has real regulatory and commercial proof, and if CASGEVY keeps compounding while just one owned franchise in in vivo editing or cell therapy clears convincing human proof, the stock can rerate from cash-plus-optionality to a durable multi-asset editing platform by 2031.

Last Economy Alignment

AI helps this company design edits, learn faster across programs, and improve manufacturing, but value still depends on regulated clinical proof and hard-to-scale care delivery, so alignment is positive rather than pivotal.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.9x (from 5 most recent analyses)

Reasoning

The upside case does not need every branch of the pipeline to work. A steadier CASGEVY ramp, one clearly validated owned program, and modest platform monetization through partnering would likely be enough for investors to value the business as a real editing franchise instead of mostly a balance sheet plus distant scientific options.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not immediate liquidity. CRISPR needs CASGEVY to become a repeatable economic engine and at least one owned program to show durable, scalable human proof; otherwise the business can remain trapped between real science and incomplete monetization.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On July 1, 2026, the FDA expanded CASGEVY to patients aged 2 years and older with SCD or TDT, widening the long-run label.
The label expansion improves franchise durability, but it does not remove the current bottleneck of conditioning intensity and treatment-center throughput.
No new owned-program human data were disclosed in the last 7-10 days, so near-term stock direction still hinges on CTX460 initiation and second-half 2026 updates.

Thesis update

The core thesis is intact. The recent pediatric expansion slightly improves the durability and optionality of the commercial base, but the bigger value inflection still depends on owned-program proof.

Forecast update

The setup is a bit less asymmetric than before because the stock has already recovered somewhat while the key owned-asset proofs are still ahead.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.38

They already turned gene editing into an approved therapy and own hard-to-copy know-how in manufacturing, delivery, and regulatory execution. AI should help them discover and optimize faster, but hospital capacity, conditioning burden, and partner-led commercialization still limit how much value they can capture.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$83.52

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research